Biosimilar

Hetero Healthcare and Enzene Biosciences Launch Affordable Biosimilar Pertuzumab ‘Perzea’ for Breast Cancer Patients in India

Precision Medicine

Hetero Healthcare and Enzene Biosciences Launch Affordable Biosimilar Pertuzumab ‘Perzea’ for Breast Cancer Patients in India

26 Sep 2025

1 min read

EMA Committee Recommends AVT03, a Biosimilar to Prolia and Xgeva, for Marketing Authorisation

EMA Committee Recommends AVT03, a Biosimilar to Prolia and Xgeva, for Marketing Authorisation

23 Sep 2025

1 min read

Accord BioPharma Launches IMULDOSA®, a Ustekinumab Biosimilar at 92% Discount

Accord BioPharma Launches IMULDOSA®, a Ustekinumab Biosimilar at 92% Discount

19 Aug 2025

1 min read

Read More

Voice Of HealthCare

vohnetwork.com